Across TCGA pan-cancer cohorts, NEFHP1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of NEFHP1’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where NEFHP1 RNA is repressed in tumor relative to normal tissue. In most cancer types NEFHP1 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

PRAD, LUAD, and LUSC are the cancer types where NEFHP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEFHP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	−0.155	.012	2	view →
LUAD	All	All	+0.005	.022	2	view →
LUSC	Male	II,III,IV	+0.008	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NEFHP1 RNA expression & survival · all NEFHP1 data types